Researchers have been experimenting with mRNA for decades as a potential weapon against cancer, but they haven't had much luck -- until now. In a new study, scientists tested two groups of melanoma patients. They found nearly 79% of patients had no
Important future directions of research will be to compare and elucidate the immune pathways activated by various mRNA vaccine platforms, to improve current approaches based on these mechanisms and to initiate new clinical trials against additional disease targets.Abstract...
The results come from in-person, phone and online surveys given to people who received two doses of the mRNA vaccine, three weeks apart, between February 16 and May 15, 2021. A total of 1,183 people with a history of cancer responded to both surveys, with 17.8% undergoing treatment at ...
细胞里是1ug/ml。为了制造mRNA疫苗焦虑，这个研究组往细胞培液里多加了1000倍mRNA，根本就不是正常的mRN...
WASHINGTON, Jan. 27 (Xinhua) -- A third COVID-19 mRNA vaccine dose provides improved protection against COVID-19-associated hospitalization among immunocompromised adults, according to a new study published by the U.S. Centers for Disease Control and Prevention (CDC) Thursday. ...
Last month researchers published results of a head-to-head comparison between LUNAR-COV19 and Comirnaty, the mRNA vaccine from Pfizer-BioNTech. In that 800-person study, vaccinated participants received either five micrograms of LUNAR-COV19 or 30 micrograms of Comirnaty as a fourth dose boos...
BEIJING, June 11 (Xinhua) -- Two mRNA-based COVID-19 vaccine candidates produced by Chinese manufacturer CanSino Biologics have proven effective in preclinical trials, suggesting the potential for human tests, according to a new study published in the journal Emerging Microbes & Infections. ...
Using mRNA technology like that in the COVID-19 vaccines, researchers have demonstrated a successful way to deliver a potential HIV vaccine, researchers at Duke Human Vaccine Institute report.
Apr 7, 2021Moderna Highlights Publication of Antibody Persistence Data of its COVID-19 Vaccine out to 6 Months in the New England Journal of Medicine Feb 24, 2021Moderna Announces it has Shipped Variant-Specific Vaccine Candidate, mRNA-1273.351, to NIH for Clinical Study ...
As of March 30 2023, many mRNA vaccine candidates for COVID-19 are in preclinical trials and 43 are under evaluation in clinical trials. Of these 43, seven have advanced to phase 3 trials [250]. Much of this work involves the evaluation of new strategies to create mRNA vaccines. Unlike ...